Clinical Trials Logo

Lung Cancer Stage IV clinical trials

View clinical trials related to Lung Cancer Stage IV.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04825912 Completed - Clinical trials for Lung Cancer Stage IV

Resilience Measurement in Older Adults With Late-Stage Lung Cancer

SST Resilience
Start date: May 3, 2021
Phase: N/A
Study type: Interventional

The purpose of this study to test measures of physical and psychological resilience while using Self-System therapy (SST), to treat depression and lung-cancer-related distress in older adults (65 years and older).

NCT ID: NCT04057196 Completed - Clinical trials for Lung Cancer Stage IV

Self-System Therapy for Older Adults With Lung Cancer

Start date: April 2, 2020
Phase: N/A
Study type: Interventional

The purpose of this study to use Self-system therapy (SST), to treat depression and lung-cancer-related distress in older adults (65 years and older).

NCT ID: NCT03558165 Completed - Clinical trials for Lung Cancer Stage IV

Lung Cancer Next Generation Sequencing Using the Oncomine Comprehensive Assay

LU-NGS-2
Start date: March 1, 2018
Phase:
Study type: Observational

Currently, publicly funded standard of care testing in Ontario for stage IV lung cancer patients uses individual gene tests to look for mutations in the EGFR and ALK genes. This testing broadens treatment options for patients, however there are other gene mutations with corresponding targeted treatments that are not routinely tested for. This study will evaluate the utility and added value of using a next generation sequencing (NGS) panel, the Oncomine Comprehensive Assay v3, to profile stage IV lung cancer patients.

NCT ID: NCT03529851 Completed - Clinical trials for Lung Cancer Stage IV

Feasibility of a Web-based Patient Reported Outcome Symptom Monitoring Application in Danish Lung Cancer Patients

Start date: May 1, 2018
Phase: N/A
Study type: Interventional

The trial is a pilot study prior to a following phase III trial and is designed to test the feasibility, acceptability and technical usability of supplementary web-based follow-up in lung cancer via a patient-reported outcome application.

NCT ID: NCT03076164 Completed - Lung Cancer Clinical Trials

A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib

Start date: March 1, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine the safety, tolerability and overall response rate of trametinib when given in combination with erlotinib in patients with Stage IV or recurrent lung adenocarcinoma that cannot be treated with curative intent.